Armata Pharmaceuticals Reports Q3 2026 Results: $3.2 Million Revenue and $0. ...
Fair-Value Gain Drives GAAP Profit as Phase 3 Preparations Accelerate Related Stocks: ARMP ,
Fair-Value Gain Drives GAAP Profit as Phase 3 Preparations Accelerate Related Stocks: ARMP ,